Cargando…
Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
Treatment of melanoma patients with mRNA electroporated dendritic cells (TriMixDC-MEL) stimulates T-cell responses against the presented tumor-associated antigens (TAAs). In the current clinical trials, melanoma patients with systemic metastases are treated, requiring priming and/or expansion of pre...
Autores principales: | Benteyn, Daphné, Van Nuffel, An M. T., Wilgenhof, Sofie, Corthals, Jurgen, Heirman, Carlo, Neyns, Bart, Thielemans, Kris, Bonehill, Aude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581259/ https://www.ncbi.nlm.nih.gov/pubmed/23509826 http://dx.doi.org/10.1155/2013/976383 |
Ejemplares similares
-
Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
por: Thielemans, Kris, et al.
Publicado: (2014) -
Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
por: Wilgenhof, Sofie, et al.
Publicado: (2015) -
Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy
por: Van Nuffel, An M.T., et al.
Publicado: (2012) -
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020) -
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
por: Benteyn, Daphné, et al.
Publicado: (2013)